MetaCap

Aura Biosciences (AURA) vs Prime Medicine (PRME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aura Biosciences (AURA) has outperformed Prime Medicine (PRME) over the past year, gaining 26.3% versus a loss of 2.2%. Prime Medicine is the larger company by market cap ($791.6 million vs $715.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AURA+26.29%PRME-2.20%
+68%+19%-30%
Nov 21, 20251 yearNov 20, 2026
AURA-45.00%PRME-77.47%
+40%-29%-99%
Oct 17, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AURA versus PRME key metrics
MetricAURAPRME
Share price$6.87$3.55
Market cap$714.99M$791.62M
1-day change-1.58%-7.55%
YTD return+26.06%+2.31%
1-year return+26.29%-2.20%
5-year return-69.63%—
EPS (TTM)$-1.59$-0.97
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$4.63M
Revenue growth (YoY)—+55.28%
Net income (latest FY)$-106.19M$-201.14M
Operating margin—-4498.06%
Net margin—-4342.44%
52-week high$9.54$5.91
52-week low$4.73$2.67
Distance from 52-week high-27.95%-39.93%
Analyst consensusstrong_buybuy
Avg. price target upside+141.63%+108.17%
Average volume847.22K4.64M
Shares outstanding104.07M222.99M
Employees113146
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AURA has outperformed PRME by 28.5 percentage points over the past year.

About Aura Biosciences

AURA stock →

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees

About Prime Medicine

PRME stock →

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees

AURA vs PRME FAQ

Which is bigger, Aura Biosciences or Prime Medicine?

Prime Medicine (PRME) is larger, with a market capitalization of $791.62M compared with $714.99M for Aura Biosciences (AURA).

Which stock has performed better over the past year, AURA or PRME?

AURA returned +26.29% over the past 12 months, compared with -2.20% for PRME (price return, excluding dividends). Past performance does not predict future results.

Are Aura Biosciences and Prime Medicine in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons